iBio, Inc. completed a private placement of common stock, issuing 11,061,738 shares at $2.35 each to raise $26 million in gross proceeds, with the transaction expected to close on January 13 2026.
The company earmarked the proceeds for advancing its preclinical cardiometabolic pipeline, including the lead obesity candidate IBIO‑610 and other antibody programs, and for general working capital needs.
iBio’s quarterly burn rate is approximately $5.7 million, so the new capital extends the company’s cash runway through calendar 2028 and provides a broader window to secure partnerships or additional funding before the next dilution event. The financing also supports the company’s plan to file an Investigational New Drug application for IBIO‑610 in early 2027.
CEO and Chief Scientific Officer Martin Brenner said the deal underscores confidence in iBio’s AI‑driven discovery platform and its obesity strategy, noting that “the promising preclinical data for IBIO‑610 are highly encouraging, especially in terms of fat‑selective weight loss and long‑term weight maintenance.”
The financing represents a significant capital injection for a preclinical biotech that has historically operated with limited revenue, giving iBio the resources to continue investing in its AI platform and advance its pipeline toward clinical validation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.